Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Dengue virus serotype 1 envelope protein (E protein) is a major structural glycoprotein forming homodimers on the virion surface, organized into three β-barrel domains (DI, DII with fusion loop, DIII immunoglobulin-like for receptor binding). It mediates host cell receptor binding, low-pH triggered conformational change for membrane fusion during entry, and serves as the primary target for neutralizing antibodies. Crystal structures reveal pre- and post-fusion forms, with DIII highly immunogenic.
Neutralization by binding to domain III and preventing receptor interaction or inducing premature fusion loop exposure, Binding to domain I/II hinge for serotype-specific neutralization
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue virus serotype 1 envelope protein (DENV-1 E protein).